Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer-A Retrospective Analysis

J. Kubeš, S. Sláviková, P. Vítek, A. Haas, B. Ondrová, K. Dedečková, M. Andrlík, M. Domanský, K. Jiránková, V. Schlencová, A. Harazimová, B. Turková, T. Doležal, SFA. Al-Hamami, V. Vondráček

. 2023 ; 15 (18) : . [pub] 20230915

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015266

BACKGROUND: We retrospectively analyzed the 5-year biochemical disease-free survival (bDFS) and occurrence of late toxicity in prostate cancer patients treated with pencil beam scanning (PBS) proton radiotherapy. METHODOLOGY: In the period from January 2013 to June 2018, 853 patients with prostate cancer were treated with an ultra-hypofractionated schedule (36.25 GyE/five fractions). The mean PSA value was 6.7 (0.7-19.7) μg/L. There were 318 (37.3%), 314 (36.8%), and 221 (25.9%) patients at low (LR), favorable intermediate (F-IR), and unfavorable intermediate risk (U-IR), respectively. Neoadjuvant hormonal therapy was administered to 197 (23.1%) patients, and 7 (0.8%) patients had adjuvant hormonal therapy. The whole group of patients reached median follow-up time at 62.7 months, and their mean age was 64.8 (40.0-85.7) years. The bDFS rates and late toxicity profile were evaluated. RESULTS: Median treatment time was 10 (7-38) days. Estimated 5-year bDFS rates were 96.5%, 93.7%, and 91.2% for low-, favorable intermediate-, and unfavorable intermediate-risk groups, respectively. Cumulative late toxicity (CTCAE v4.0) of G2+ was as follows: gastrointestinal (GI)-G2: 9.1%; G3: 0.5%; genitourinary (GU)-G2: 4.3%, and no G3 toxicity was observed. PSA relapse was observed in 58 (6.8%) patients: 16 local, 22 lymph node, 4 bone recurrences, and 10 combined sites of relapse were detected. Throughout the follow-up period, 40 patients (4.7%) died, though none due to prostate cancer. CONCLUSION: Ultra-hypofractionated proton beam radiotherapy is an effective treatment for low- and favorable intermediate-risk prostate cancer, with long-term bDFS rates comparable to other techniques. It is promising for unfavorable intermediate-risk prostate cancer and has acceptable long-term GI and favorable GU toxicity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015266
003      
CZ-PrNML
005      
20240902141211.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers15184571 $2 doi
035    __
$a (PubMed)37760540
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kubeš, Jiri $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic $u Department of Health Care Disciplines and Population Protection, Faculty of Biomedical Engineering, Czech Technical University Prague, Sítná Square 3105, 272 01 Kladno, Czech Republic
245    10
$a 5-Years Analysis of Effectivity and Toxicity of Ultra-Hypofractionated Proton Radiotherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer-A Retrospective Analysis / $c J. Kubeš, S. Sláviková, P. Vítek, A. Haas, B. Ondrová, K. Dedečková, M. Andrlík, M. Domanský, K. Jiránková, V. Schlencová, A. Harazimová, B. Turková, T. Doležal, SFA. Al-Hamami, V. Vondráček
520    9_
$a BACKGROUND: We retrospectively analyzed the 5-year biochemical disease-free survival (bDFS) and occurrence of late toxicity in prostate cancer patients treated with pencil beam scanning (PBS) proton radiotherapy. METHODOLOGY: In the period from January 2013 to June 2018, 853 patients with prostate cancer were treated with an ultra-hypofractionated schedule (36.25 GyE/five fractions). The mean PSA value was 6.7 (0.7-19.7) μg/L. There were 318 (37.3%), 314 (36.8%), and 221 (25.9%) patients at low (LR), favorable intermediate (F-IR), and unfavorable intermediate risk (U-IR), respectively. Neoadjuvant hormonal therapy was administered to 197 (23.1%) patients, and 7 (0.8%) patients had adjuvant hormonal therapy. The whole group of patients reached median follow-up time at 62.7 months, and their mean age was 64.8 (40.0-85.7) years. The bDFS rates and late toxicity profile were evaluated. RESULTS: Median treatment time was 10 (7-38) days. Estimated 5-year bDFS rates were 96.5%, 93.7%, and 91.2% for low-, favorable intermediate-, and unfavorable intermediate-risk groups, respectively. Cumulative late toxicity (CTCAE v4.0) of G2+ was as follows: gastrointestinal (GI)-G2: 9.1%; G3: 0.5%; genitourinary (GU)-G2: 4.3%, and no G3 toxicity was observed. PSA relapse was observed in 58 (6.8%) patients: 16 local, 22 lymph node, 4 bone recurrences, and 10 combined sites of relapse were detected. Throughout the follow-up period, 40 patients (4.7%) died, though none due to prostate cancer. CONCLUSION: Ultra-hypofractionated proton beam radiotherapy is an effective treatment for low- and favorable intermediate-risk prostate cancer, with long-term bDFS rates comparable to other techniques. It is promising for unfavorable intermediate-risk prostate cancer and has acceptable long-term GI and favorable GU toxicity.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sláviková, Silvia $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic
700    1_
$a Vítek, Pavel $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic $u Department of Oncology, 1st Faculty of Medicine and General University Hospital, Charles University, Kateřinská 32, 121 08 Praha, Czech Republic
700    1_
$a Haas, Alexandra $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic
700    1_
$a Ondrová, Barbora $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic
700    1_
$a Dedečková, Kateřina $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic
700    1_
$a Andrlík, Michal $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic $1 https://orcid.org/0000000165815583 $7 xx0322119
700    1_
$a Domanský, Martin $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic $7 xx0317400
700    1_
$a Jiránková, Kateřina $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic $7 xx0316963
700    1_
$a Schlencová, Veronika $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic
700    1_
$a Harazimová, Anh $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic
700    1_
$a Turková, Barbora $u Value Outcomes Ltd., Václavská 316/12, 120 00 Praha, Czech Republic $1 https://orcid.org/0000000230755004
700    1_
$a Doležal, Tomáš $u Value Outcomes Ltd., Václavská 316/12, 120 00 Praha, Czech Republic
700    1_
$a Al-Hamami, Sarah Falah Abass $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic $7 xx0322129
700    1_
$a Vondráček, Vladimír $u Proton Therapy Center Czech, Budínova 1a, 180 00 Prague, Czech Republic $1 https://orcid.org/0000000253010101
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 15, č. 18 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37760540 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20240902141209 $b ABA008
999    __
$a ok $b bmc $g 1997074 $s 1201628
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 18 $e 20230915 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace